Sage Group plc Unsponsored ADR (SGPYY)
OTC PINK OTC PINK Primary 
Pomerantz Law Firm Announces the Filing of a Class Action Against Sage Therapeutics, Inc. and Certain Officers – SAGE
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06511, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sage securities between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Shareholders With Losses In Sage Therapeutics Inc Are Invited To Contact The Schall Law Firm About An Investigation Into Potential Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Looking Into Possible Securities Infractions By Sage Therapeutics Inc And Investors Are Urged To Participate
LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Meta strikes geothermal energy deal with Sage Geosystems to power data centers
Facebook owner Meta Platforms struck a deal to buy up to 150 MW of geothermal power from Sage Geosystems to supply its data centers, as it races to build out the infrastructure to support its massive energy-hungry artificial intelligence investments, it said in a statement on Monday.
An Inquiry Has Been Launched Into Sage Therapeutics Inc For Securities Fraud And The Schall Law Firm Invites Impacted Shareholders To Help
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Seeking Investors In Sage Therapeutics Inc To Join An Investigation Into Possible Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Inquiring Into Sage Therapeutics Inc For Securities Fraud And Stockholders Are Invited To Play A Part
LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sage Therapeutics Inc Is Being Looked Into By The Schall Law Firm For Securities Law Violations And Investors Are Asked To Join
LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Into Sage Therapeutics Inc For Possible Securities Fraud Has Been Opened By The Schall Law Firm And Affected Shareholders Are Urged To Participate
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Investigating Sage Therapeutics Inc. For Possible Securities Law Violations And Seeks Shareholders To Participate
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The Schall Law Firm Is Looking Into Sage Therapeutics Inc. For Securities Violations And Invites Investors With Losses To Join In Conversation
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
